Top & Trending
This is the ACS Print Brand Style Guide targeted for Members (volunteers, etc.) This is current as of Winter 2017/18.
Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment)
Fidaxomicin is an antibiotic that belongs to the class of the macrocyclics and is indicated for the treatment of CDI. In clinical trials, fidaxomicin, when compared to vancomycin, was non-inferior for the clinical cure of patients with CDI and superior for the reduction of recurrence rates, with a greater sustained response after 30 days. Of the